Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

A Case of New-onset Autoimmune Type-1 Diabetes Mellitus Following COVID-19 Infection

Author(s): Işılay Taşkaldıran* and Aslı Nar

Volume 23, Issue 11, 2023

Published on: 05 June, 2023

Page: [1455 - 1457] Pages: 3

DOI: 10.2174/1871530323666230418092121

Price: $65

Abstract

Background: After COVID-19 infection, various mechanisms may initiate an increased risk of developing DM. This study presented a newly developed autoimmune Type 1 DM (T1DM) case in an adult patient after a SARS-CoV-2 infection.

Case Presentation: A 48-year-old male patient presented with complaints of weight loss and blurred vision. His blood sugar and HbA1c were measured as 557 mg/dl and 12.6%, respectively. His medical records showed no known diagnosis of DM. He had a SARS-CoV-2 infection 4 weeks ago. Then, we diagnosed DM and started basal-bolus insulin therapy. C-peptides and autoantibodies were requested from the patient to explore the etiology of diabetes. Glutamic acid decarboxylase (GAD) antibody was > 2000 U/mL (ref: 0-10); therefore, the patient was accepted as having autoimmune T1DM. New-onset DM cases triggered by COVID-19 have increasingly been reported recently. SARS-CoV-2 virus, using the ACE2 receptor in the pancreas, can enter beta cells and causes damage to these islets and impaired insulin secretion, leading to acute diabetes mellitus. In addition, the abnormal immunity elicited by SARS-CoV-2 can also induce autoimmune destruction of pancreatic islet cells.

Conclusion: T1DM may be an uncommon but possible complication due to the COVID-19 virus among genetically predisposed individuals. Overall, the case highlights the importance of preventive measures, such as vaccination, to protect against COVID-19 and its complications.

Keywords: COVID-19, autoimmune, diabetes mellitus, SARS-CoV-2, glutamic acid decarboxylase, antibody.

« Previous
Graphical Abstract

[1]
Wu, F.; Zhao, S.; Yu, B.; Chen, Y.M.; Wang, W.; Song, Z.G.; Hu, Y.; Tao, Z.W.; Tian, J.H.; Pei, Y.Y.; Yuan, M.L.; Zhang, Y.L.; Dai, F.H.; Liu, Y.; Wang, Q.M.; Zheng, J.J.; Xu, L.; Holmes, E.C.; Zhang, Y.Z. A new coronavirus associated with human respiratory disease in China. Nature, 2020, 579(7798), 265-269.
[http://dx.doi.org/10.1038/s41586-020-2008-3] [PMID: 32015508]
[2]
Mateu-Salat, M.; Urgell, E.; Chico, A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. J. Endocrinol. Invest., 2020, 43(10), 1527-1528.
[http://dx.doi.org/10.1007/s40618-020-01366-7] [PMID: 32686042]
[3]
Vuille-Lessard, É.; Montani, M.; Bosch, J.; Semmo, N. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J. Autoimmun., 2021, 123, 102710.
[http://dx.doi.org/10.1016/j.jaut.2021.102710] [PMID: 34332438]
[4]
Chekhlabi, N.; Haoudar, A.; Echcharii, N.; Ettair, S.; Dini, N. New-onset diabetes with ketoacidosis precipitated by COVID-19 in children: A report of two cases. Case Rep. Pediatr., 2021, 2021, 1-4.
[http://dx.doi.org/10.1155/2021/5545258] [PMID: 34327034]
[5]
Boddu, S.K.; Aurangabadkar, G.; Kuchay, M.S. New onset diabetes, type 1 diabetes and COVID-19. Diabetes Metab. Syndr., 2020, 14(6), 2211-2217.
[http://dx.doi.org/10.1016/j.dsx.2020.11.012] [PMID: 33395782]
[6]
Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229), 1054-1062.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[7]
Yang, J.K.; Lin, S.S.; Ji, X.J.; Guo, L.M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol., 2010, 47(3), 193-199.
[http://dx.doi.org/10.1007/s00592-009-0109-4] [PMID: 19333547]
[8]
Craig, M.E.; Nair, S.; Stein, H.; Rawlinson, W.D. Viruses and type 1 diabetes: A new look at an old story. Pediatr. Diabetes, 2013, 14(3), n/a.
[http://dx.doi.org/10.1111/pedi.12033] [PMID: 23517503]
[9]
Jaeckel, E.; Manns, M.; Herrath, M. Viruses and diabetes. Ann. N. Y. Acad. Sci., 2002, 958(1), 7-25.
[http://dx.doi.org/10.1111/j.1749-6632.2002.tb02943.x] [PMID: 12021080]
[10]
Tittel, S.R.; Rosenbauer, J.; Kamrath, C.; Ziegler, J.; Reschke, F.; Hammersen, J.; Mönkemöller, K.; Pappa, A.; Kapellen, T.; Holl, R.W. Did the COVID-19 lockdown affect the incidence of pediatric type 1 diabetes in Germany? Diabetes Care, 2020, 43(11), e172-e173.
[http://dx.doi.org/10.2337/dc20-1633] [PMID: 32826282]
[11]
Barrett, C.E.; Koyama, A.K.; Alvarez, P.; Chow, W.; Lundeen, E.A.; Perrine, C.G.; Pavkov, M.E.; Rolka, D.B.; Wiltz, J.L.; Bull-Otterson, L.; Gray, S.; Boehmer, T.K.; Gundlapalli, A.V.; Siegel, D.A.; Kompaniyets, L.; Goodman, A.B.; Mahon, B.E.; Tauxe, R.V.; Remley, K.; Saydah, S. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years-United States, March 1, 2020-June 28, 2021. MMWR Morb. Mortal. Wkly. Rep., 2022, 71(2), 59-65.
[http://dx.doi.org/10.15585/mmwr.mm7102e2] [PMID: 35025851]
[12]
Denina, M.; Trada, M.; Tinti, D.; Funiciello, E.; Novara, C.; Moretto, M.; Rosati, S.; Garazzino, S.; Bondone, C.; De Sanctis, L. Increase in newly diagnosed type 1 diabetes and serological evidence of recent SARS-CoV-2 infection: Is there a connection? Front. Med., 2022, 9, 927099.
[http://dx.doi.org/10.3389/fmed.2022.927099] [PMID: 35966867]

Rights & Permissions Print Cite
Article Metrics
25
2
© 2024 Bentham Science Publishers | Privacy Policy